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Abstract: An efficient molecular simulation methodology has been developed for the evaluation of the 
druggability (ligandability) of a protein.   Previously proposed techniques were designed to assess the 
druggability of crystallographic structures and cannot be tightly coupled to molecular dynamics (MD) 
simulations. By contrast the present approach, JEDI (‘’Just Exploring Druggability at protein 
Interfaces’’), features a druggability potential made of a combination of empirical descriptors that can 
be collected "on-the-fly" during MD simulations. Extensive validation studies indicate that JEDI 
analyses discriminate druggable and nondruggable protein binding site conformations with accuracy 
similar to alternative methodologies, and at a fraction of the computational cost. Since the JEDI function 
is continuous and differentiable, the druggability potential can be used as collective variable to rapidly 
detect cryptic druggable binding sites in proteins with a variety of MD free energy methods. Protocols 
for applications to flexible docking problems are outlined. 
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Introduction 
The development of a new medicine is a long and expensive process subjected to high attrition rates.
1
 
Over the last decades, around 60% of drug discovery projects failed to identify viable leads able to 
modulate adequately the activity of a protein target.
2
 Analyses of the sequenced human genome indicate 
that less than 50% of disease-involved genes code for druggable proteins.
3,4
 A protein target found to be 
nondruggable late in the drug discovery process is a significant waste of time and expense in the 
pharmaceutical industry. Accordingly, an early assessment of druggability offers the opportunity to 
focus efforts on tractable targets, thereby reducing the rate of failure.
5
 The concept of druggability is 
ambiguous because it has been used in many different fields to describe, in a different context, the 
properties of genes, proteins and ligands. In the context of structure-based drug design, protein 
druggability is often related to the ability of a therapeutic target to bind a drug-like small molecule, 
leaving aside many important facets of the drug discovery and development process such as selectivity, 
toxicology or pharmacokinetics.
3
 Since druggability is closely linked to the notion of binding site in this 
specific context, the terms “bindability” or “ligandability” have also been proposed as alternatives.6,7  
This report focuses on the use of computation for structure-based evaluation of protein 
druggability. The idea of relating binding site energetics to structural descriptors was explored as early 
as in 1985 with the Grid program of Goodford, and other related methods.
8-11
 As interest in druggability 
developed in the last fifteen years, more recent efforts have focused on correlating directly structural 
descriptors to druggability. An early effort was contributed by Hadjuk and coworkers.
12
 NMR-based 
fragment screening was used to develop a mathematical model for druggability measurements whereby 
structural descriptors were correlated to NMR hit-rates. The methodology is based on the assumption 
that a druggable cavity tends to bind more fragments than a nondruggable pocket. A second approach, 
called MAPPOD, was published by Cheng et al. shortly after.
13
 The authors proposed a scoring function 
to assess the maximal affinity between a small molecule and a binding site based on physicochemical 
and geometric features. This study also introduced a new category of proteins that are neither 
 3 
‘druggable’ nor ‘nondruggable’, but are instead “difficult” to target with small molecules. The 
suggestion was that this category of proteins should be targeted with highly polar molecules 
administrated as pro-drugs. These early contributions have paved the way for a similar class of 
computational methods that aim to detect and evaluate potential binding sites at protein surfaces. For 
instance, the public dataset compiled for MAPPOD was used to parameterize Dscore, a druggability 
function coupled with the pocket detector SiteMap.
14,15
 Dscore is a simple linear combination of three 
descriptors reflecting the volume, enclosure and hydrophobicity of the binding site. Schmidtke et al. 
have recently developed a fast methodology based on a new publically accessible dataset.
16
 The 
approach features a logistic regression analysis to extract local and global hydrophobic descriptors of a 
protein pocket. Another recent structure-based approach published in the field is the Drugpred method.
17
 
The Drugpred scoring function is based on a large freely accessible non-redundant protein dataset and 
was derived using partial least-squares projection. Drugpred appears to be less sensitive to small binding 
site structural modifications that do not dramatically affect pocket properties.
17
 
The above described methods were designed to assess the druggability of a crystallographic 
protein structure. However, it is well known that sometimes a few local structural rearrangements 
around a protein binding site can profoundly influence the binding affinity of a small molecule to its 
target.
18,19
 Accordingly, a second class of druggability prediction algorithms based on molecular 
dynamics (MD) simulations have been proposed.
20-22
 One of the first method based on classical 
molecular dynamics simulations was published by Seco et al.
20
 In this grid-based approach, an explicit 
restrained MD simulation of a protein is performed in the presence of a given concentration of isopropyl 
alcohol. The binding propensities of the probe at the protein surface are then back-computed to evaluate 
spatially resolved binding free energies. A similar protocol was recently applied on different systems 
using several diverse probes.
22
 The authors showed that probe molecules could induce both local and 
global structural rearrangements of the protein, leading to increases in target druggability. Nevertheless 
a frequent concern with these techniques is that the observed conformational changes reflect 
denaturation of the protein due to high probe concentrations. Thus judicious use of positional restraints 
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is required to limit the occurrence of undesirable conformational changes. Also, probe diffusion 
necessary to compute binding propensities in buried cavities can be very slow with standard MD 
approaches. 
To overcome the limitations of current MD based druggability prediction methods, this report 
introduces the JEDI algorithm (‘’Just Exploring Druggability at protein Interfaces’’). JEDI has been 
designed to evaluate protein druggability "on-the-fly" during MD simulations without using organic 
probes or protein restraints. The druggability function relies on a set of geometric parameters describing 
the volume, the enclosure and the hydrophobicity of a binding site. The JEDI scoring function is fast, 
continuous and differentiable. Accordingly, the JEDI druggability descriptor can be used to construct 
artificial druggability potentials that are designed to bias sampling of protein binding site conformations 
similar to a training set with the aid of a druggability force applied during a MD simulation. JEDI has 
been implemented in the software PLUMED 1.3 to enable biased molecular dynamics simulations with 
a variety of free-energy calculations techniques and diverse popular MD engines.
23
 The methodology 
was parameterized using the freely accessible Druggable Cavity Directory (DCD) dataset.
16
 The 
sensitivity of the method to binding site conformational changes was tested with a compiled dataset of 
cryptic binding sites. Detailed druggability assessments have also been performed on the fly during 
unbiased and biased MD simulations of a test protein, VHL. This demonstrated the potential for JEDI 
analyses to detect cryptic druggable binding sites in proteins and to deliver conformations suitable as 
input for subsequent docking calculations. 
 
Methods 
Datasets. Protein structures were taken from the Non Redundant Druggability Dataset (NRDD) 
in the Druggable Cavity Directory compiled by Schmidtke et al.
16
 A set of 63 unique proteins has been 
used to parameterize the JEDI scoring function. Each protein has been assigned by the authors of the 
original study an experimental druggability value from 1 to 10 (from less druggable to more druggable) 
according to its capability to bind a drug-like compound. The dataset can be further divided into three 
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categories: non-druggable (DCDscore 1 to 4), difficult (DCDscore 5 to 7) and druggable (DCDscore 8 to 10). 
In order to benchmark JEDI against an existing methodology, druggability calculations were performed 
on the energy-minimized structures of the training dataset using the program fpocket.
16,24
 A detailed list 
of the dataset is given in the supporting information, including druggability scores obtained with both 
approaches (SI Table S1). A validation dataset, called the hidden pocket dataset, has also been 
compiled. Each protein in this dataset is represented by two different structures that exhibit 
conformational variability in the binding site region that correlates with variations in the binding 
affinities of known ligands.  
 Protocol overview. JEDI is a grid-based approach. The methodology includes three major steps 
(Figure 1A). First, a region of interest where the druggability evaluation will be conducted must be 
defined. This area can be located anywhere in the protein structure in principle, but in this report efforts 
are focused on evaluating the druggability of regions known to contain a binding site. Thus spatial 
regions to analyze were defined from the position of known ligands. A large 3D cubic grid with 1.5 Å 
spacing between grid points is initially positioned around the region of interest. Next, only grid points 
within 6 Å of one ligand atom were retained. All protein heavy atoms within 3 Å of a grid point are then 
selected for druggability calculations and this set of atoms is referred as the ‘binding site region’. This 
setup is then followed by either a single point calculation or MD simulations with druggability 
evaluated at regular intervals in unbiased simulations, or at each time-step for MD simulations biased 
with the JEDI potential. Every druggability assessment requires that the ‘activity’ of all grid points is 
evaluated, with grid points classified as inactive, partially active or fully active according to their 
geometric position in the binding site. Then, volume and hydrophobicity descriptors that depend on grid 
point activities and local geometric arrangements of protein atoms are computed in order produce a 
conformation-dependent protein druggability score.  
To avoid errors in the druggability predictions due to diffusion of the protein over the course of 
an MD simulation, the Cartesian coordinates of the grid points are re-evaluated prior to each 
druggability assessment. Firstly, the distance vector between the center of mass of the protein atoms in 
 6 
the binding site region in the conformation at the n-th step of the MD simulation (rcom,t=n) and the initial  
protein conformation (rcom,t=0) is evaluated. Then, the rotation matrix that best fits the protein backbone 
atoms of the entire protein onto their coordinates at t = 0 is computed using the Kabsch algorithm.
25
 
Finally, the resulting translation vector and rotation matrix are used to transform the grid point Cartesian 
coordinates at t = 0 into grid point Cartesian coordinates at t = n. 
 Scoring Function. The JEDI druggability score is calculated as a linear combination of two 
partial-least squared derived descriptors reflecting the volume, and the hydrophobicity (eq 1). 
 𝐽𝐸𝐷𝐼𝑠𝑐𝑜𝑟𝑒 = 𝑉𝑑𝑟𝑢𝑔𝑙𝑖𝑘𝑒(𝛼𝑉𝑎 + 𝛽𝐻𝑎 + 𝛾) 
(1) 
where Vdruglike, Va and Ha represent respectively the drug-like volume descriptor, the pocket volume 
descriptor and the pocket hydrophobicity. and γare constants of the model derived by multiple 
linear regressions against a training set.  All the descriptors presented below are based on spline 
functions such that the JEDI potential is continuous and at least twice differentiable. Two forms of 
spline functions have been used operating on variables v and k (Figure 1C). The first one turns “off” 
with v starting at k at vmin, reaching 0 at vmin+Δ (eq 2). 
 
𝑆𝑣
𝑜𝑓𝑓(𝑘, 𝑣𝑚𝑖𝑛 , ∆) = {
𝑘 𝑖𝑓 𝑚 < 0
𝑘[(1 − 𝑚2)2(1 + 2𝑚2)] 𝑖𝑓 0 ≤ 𝑚 ≤ 1
0 𝑖𝑓 𝑚 > 1
 (2) 
where 𝑚 =
𝑣−𝑣𝑚𝑖𝑛
∆
. The second form turns “on” from 0 to k along an interval Δ (eq 3).  
 
     𝑆𝑣
𝑜𝑛(𝑘, 𝑣𝑚𝑖𝑛 , ∆) = {
0 𝑖𝑓 𝑚 < 0
𝑘[1 − (1 − 𝑚2)2(1 + 2𝑚2)] 𝑖𝑓 0 ≤ 𝑚 ≤ 1
𝑘 𝑖𝑓 𝑚 > 1
 (3) 
The active volume descriptor V of the binding site is given by equation 4:  
 
𝑉 = ∑ 𝑎𝑖
𝑁
𝑖=1
𝑉𝑔  (4) 
where N is total number of grid points, Vg is the volume of space covered by a grid point. To capture the 
shape of the pocket, each grid point is assigned an activity score ai between 0 and 1 (inactive to active), 
according to its geometric position inside the binding pocket (eq 5).  
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 𝑎𝑖 = 𝑆𝐵𝑆𝑖
𝑜𝑓𝑓(1.0, 𝐵𝑆𝑖, ∆𝐵𝑆)𝑆𝑚𝑖𝑛𝑑𝑖
𝑜𝑛 (1.0, 𝐶𝐶𝑚𝑖𝑛𝑑 , ∆𝐶𝐶)𝑆𝑒𝑥𝑝𝑜𝑠𝑢𝑟𝑒𝑖
𝑜𝑛 (1.0, 𝐸𝑚𝑖𝑛 , ∆𝐸) (5) 
The first term of eq 5 gradually turns off grid points according their distances from the region of 
interest. This term is optional, but is useful to ensure that fluctuations in druggability scores are not 
unduly influenced by conformational changes that are remote from the protein region of interest. The 
minimum distance BSi between a grid point i and the M atomic coordinates defining the binding site 
region is calculated as: 
 
𝐵𝑆𝑖 =
𝜃
ln (∑ exp (
𝜃
‖𝒓𝑖𝑗‖
)𝑀𝑗=1 )
 
(6) 
With =50.0 Å and 𝒓𝑖𝑗 = 𝒓𝑔𝑖 − 𝒓𝑝𝑗, where rgi and rpj are respectively the position vectors of grid point i 
and protein atom j belonging to the binding site region. The second term in equation 5 causes grid points 
that overlap with protein atoms to be gradually inactivated (Figure 1B). The minimum distance mindi 
between grid points and protein atoms is calculated with an equation similar to eq 6. The third term in 
equation 5 gradually inactivates solvent exposed grid points (Figure 1B).  
 
𝑒𝑥𝑝𝑜𝑠𝑢𝑟𝑒𝑖 = ∑ [𝑆𝑚𝑖𝑛𝑑𝑘
𝑜𝑓𝑓 (1.0, 𝐶𝐶2𝑚𝑖𝑛 , Δ𝐶𝐶2)𝑆‖𝒓𝑖𝑘‖
𝑜𝑛 (1.0, 𝐺𝑃1𝑚𝑖𝑛, Δ𝐺𝑃1)𝑆‖𝒓𝑖𝑘‖
𝑜𝑓𝑓 (1.0, 𝐺𝑃2𝑚𝑖𝑛, Δ𝐺𝑃2)]
𝑁
𝑘=1
 (7) 
where CC2min /ΔCC2 control the distance below which a grid point is considered as interacting with the 
protein. GP1min /ΔGP1 and GP2min /ΔGP2 are used to select grid points at a given distance interval from 
the grid point i in order to penalize solvent exposed grid points. With the default values presented in 
Table 1, a maximum of 44 grid points can be selected around a given grid point i and the maximum 
value of exposurei is 23.97 with the present parameterization. Thus to summarize a grid point achieves a 
high activity value (maximum 1) if it is neither too close nor too far from the protein atoms that form the 
binding site region of interest.  
The active volume V is then converted in a pocket volume descriptor Va using equation 8. 
 
𝑉𝑎 =
𝑉
𝑉𝑚𝑎𝑥
 (8) 
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where Vmax is the maximum active volume descriptor. This constant was set to be equal to the maximum 
active volume V calculated for protein binding sites in the ‘’druggable’’ category of the DCD dataset. 
Accordingly, a cavity presenting the characteristics of a typical small-molecule binding site will have a 
typical Va value in the interval [0.0,1.0]. In order to penalize overly large or overly small cavities that 
are not suitable for drug-like small molecules, the descriptor Vdruglike is also computed with eq 9.  
 𝑉𝑑𝑟𝑢𝑔𝑙𝑖𝑘𝑒 = 𝑆𝑉
𝑜𝑓𝑓(1.0, 𝑉𝑚𝑎𝑥 , Δ𝑉𝑚𝑎𝑥)𝑆𝑉
𝑜𝑛(1.0, 𝑉𝑚𝑖𝑛 , Δ𝑉𝑚𝑖𝑛) (9) 
where Vmin is equal to 0 Å
3
 by default. Analysis of pockets from the DCD dataset suggested a ΔVmin 
value of 36 Å
3
. For simplicity, the same value was used for ΔVmax . The effect is that cavities that differ 
substantially in active volume from those present in the training set will have a low value of Vdruglike. In 
turn this will assign a low JEDIscore to cavities that differ markedly from the training set. This parameter 
may be easily tuned if cavities for ligands that differ substantially from those present in the DCD 
training set are desired. 
The active grid hydrophobicity function captures the average hydrophobicity of the active grid points 
and is given by eq 10: 
 
𝐻𝑎 =
1
𝑉
∑ (𝐻𝑖𝑎𝑖)
𝑁
𝑖=1
 (10) 
where the hydrophobicity score Hi of the grid point i is calculated as 
 
𝐻𝑖 =
𝑎𝑝𝑜𝑙𝑎𝑟𝑖
𝑎𝑝𝑜𝑙𝑎𝑟𝑖 + 𝑝𝑜𝑙𝑎𝑟𝑖
 (11) 
where apolari and polari are function of the number of apolar (C and S) and polar (O and N) protein 
atoms within the distance rhydro defined by equations 12a and 12b: 
 
𝑎𝑝𝑜𝑙𝑎𝑟𝑖 = ∑ 𝑆‖𝒓𝑖𝑗‖
𝑜𝑓𝑓 (𝑎𝑖, 𝑟ℎ𝑦𝑑𝑟𝑜 , Δ𝑟ℎ𝑦𝑑𝑟𝑜)
𝑀𝑎𝑝𝑜𝑙𝑎𝑟
𝑗=1
  (12a) 
 
𝑝𝑜𝑙𝑎𝑟𝑖 = ∑ 𝑆‖𝒓𝑖𝑗‖
𝑜𝑓𝑓 (𝑎𝑖, 𝑟ℎ𝑦𝑑𝑟𝑜 , Δ𝑟ℎ𝑦𝑑𝑟𝑜)
𝑀𝑝𝑜𝑙𝑎𝑟
𝑗=1
  (12b) 
where Mapolar and Mpolar are the total number of apolar and polar protein atoms in the binding site region.  
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JEDI derivatives. Because the JEDI potential is based on functions that are continuous and 
differentiable, the gradient with respect to the Cartesian coordinates 𝑥𝑝𝑗, 𝑦𝑝𝑗 , 𝑧𝑝𝑗  of the j protein atoms 
in the binding site region can be calculated using the following equation: 
 
∇𝐽𝐸𝐷𝐼𝑠𝑐𝑜𝑟𝑒 = ∑ (
𝜕𝐽𝐸𝐷𝐼𝑠𝑐𝑜𝑟𝑒
𝜕𝑥𝑝𝑗
+
𝜕𝐽𝐸𝐷𝐼𝑠𝑐𝑜𝑟𝑒
𝜕𝑦𝑝𝑗
+
𝜕𝐽𝐸𝐷𝐼𝑠𝑐𝑜𝑟𝑒
𝜕𝑧𝑝𝑗
)
𝑀
𝑗=1
 (13) 
where M is the number of protein atoms in the binding site region, 
𝜕𝐽𝐸𝐷𝐼𝑠𝑐𝑜𝑟𝑒
𝜕𝑥𝑝𝑗
, 
𝜕𝐽𝐸𝐷𝐼𝑠𝑐𝑜𝑟𝑒
𝜕𝑦𝑝𝑗
 and 
𝜕𝐽𝐸𝐷𝐼𝑠𝑐𝑜𝑟𝑒
𝜕𝑧𝑝𝑗
 are 
the partial derivatives with respect to the Cartesian coordinates of protein atom j. The derivatives of the 
JEDI potential with respect to the grid Cartesian coordinates do not need to be calculated as the grid is 
frozen during MD time-steps. By application of the product rule: 
 𝜕𝐽𝐸𝐷𝐼𝑠𝑐𝑜𝑟𝑒
𝜕𝑥𝑝𝑗
= 𝐽𝐸𝐷𝐼𝑠𝑐𝑜𝑟𝑒 [
1
𝑉𝑑𝑟𝑢𝑔𝑙𝑖𝑘𝑒
𝜕𝑉𝑑𝑟𝑢𝑔𝑙𝑖𝑘𝑒
𝜕𝑥𝑝𝑗
+
1
𝛼𝑉𝑎 + 𝛽𝐻𝑎 + 𝛾
(𝛼
𝜕𝑉𝑎
𝜕𝑥𝑝𝑗
+ 𝛽
𝜕𝐻𝑎
𝜕𝑥𝑝𝑗
)] (14) 
Similar expressions can be derived for the partial derivatives with respect to 𝑦𝑝𝑗  and 𝑧𝑝𝑗 . A 
detailed derivation of all partial derivatives in equation 14 is given in the supplementary inforamation. 
 JEDI optimization. The parameters of the JEDI model were optimized using the python module 
PyEvolve.
26
 After investigation, only the CCmind, ΔE, ΔCC2 and rhydro variables were selected for 
optimization using a range of physically plausible values (SI Table S2). An elitist genetic algorithm was 
then iterated for 50 generations on a population of 40 individuals. The fitness function was defined to 
maximize the r
2
 of JEDIscore vs DCDscore values after a Partial Least Squares regression. Uncertainties in 
the JEDIscore parameters were determined with 100 iterations of bootstrapping using a split of 0.7/0.3 for 
the training and validation sets.  
 MD simulations. Proteins, ligands and cofactors were prepared using the python script Protein 
Preparation Wizard developed by Schrödinger and available in Maestro.
27
 First, missing hydrogen 
atoms were added to the structure to assign the appropriate bond number and formal charge. Then, 
proteins were manually verified to avoid incomplete side chains and steric clashes. Molecular dynamics 
simulations have been performed using GROMACS 4.5.5 combined with PLUMED 1.3.
23,28
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Simulations were carried out in implicit solvent using the Generalized Born model and the Onufriev-
Bashford-Case method to calculate the Born radii with a cutoff of 20 Å.
29,30
 An energy minimization 
was performed using the steepest descent algorithm to reach the convergence parameter of 300 kJ.mol
-
1
.nm
-1
 of maximum force change. Then, production runs of 50 ns were performed using a time step of 
2.0 fs. Systems were maintained at a constant temperature of 310 K using a stochastic Berendsen 
thermostat with a coupling constant of 1.0 ps.
31
 The force field Amber99sb-ILDN was used for the 
proteins and the GAFF force field has been used for ligands and cofactors.
32,33
 The GAFF parameters 
for the ligands and the cofactors were obtained by using the software acpype, in combination with the 
antechamber utility from the AMBER12 software package.
34,35
 A new atom type was created to 
represent grid points. To avoid interactions between the protein atoms and the grid points, the Lennard-
Jones parameters  and  and the atomic partial charges of grid points were equal to zero. All grid 
points are frozen in space during energy minimization and molecular dynamics time-steps.   
 Umbrella sampling simulations. Several umbrella sampling calculations were performed using 
the following biasing potential: 
𝑈𝐽𝐸𝐷𝐼(𝑠(𝒓)) = 𝜅(𝑠(𝒓) − 𝑠0)
2 (15) 
where s(r) is the JEDIscore of protein binding site conformation r,  is the force constant of the biasing 
potential, and s0 is a target value for JEDIscore.
36
 Several biased MD simulations were performed by 
varying  and s0 for different systems. The resulting trajectories were clustered to identify the most 
likely conformations associated with a given set of (, s0) values. The single linkage clustering approach 
as implemented in GROMACS was used to identify the most representative conformations of each 
resulting trajectory. The RMSD cluster cutoff was set  to 1 Å. RMSD calculations were performed using 
the coordinates of heavy atoms constituting the binding site region, excluding atoms that can form 
symmetry equivalent conformations (e.g. Valine Cγ atoms). Finally, cluster homogeneity was manually 
checked.  
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Docking calculations. Several representative protein structures were extracted from the 
trajectories to perform docking calculations. The Maestro software was used to prepare input files for 
both receptors and ligands.
27
 Protonation states of binding site Histidine residues were chosen to be 
consistent with those from the MD simulations (in particular, His110 and His115 were protonated on the 
-nitrogen atom). Docking calculations were performed with the software Autodock Vina and the 
Autodock/Vina plugin for pymol.
37,38
 For each complex, the same docking grid was used, and up to 
twenty poses were generated. Different protocols featuring a fully rigid receptor or allowing side-chain 
flexibility of selected residues were used.  
 
Results and Discussion 
 
Choice of descriptors.  
The druggability score of the JEDI methodology is based on a linear combination of structural 
descriptors characterizing the volume and the hydrophobicity of a cavity. The choice of those collective 
variables were influenced by the literature.
6,12,13,16,17,39
 A rule-based method published by Perola et al. 
suggested five suitable descriptors: volume, depth, enclosure, percentage of charged residues and 
hydrophobicity. These descriptors summarize a general consensus fairly well.
40
 After investigation, only 
two descriptors have been retained: the active volume and the hydrophobicity. An early version of JEDI 
was also including a descriptor capturing the degree of buriedness of the binding site. The buriedness, as 
described by Volkamer et al., was captured as the ratio between the number of hull grid points in contact 
with the protein surface and the total number of hull grid points.
39
 Here hull grid points are defined as in 
Volkamer et al. and correspond to the outer layer of active grid points that define the shape of a binding 
site. After preliminary investigations, this descriptor was not found to contribute significantly to the 
druggability prediction. This is likely because the current definition of the active volume descriptor is 
penalizing solvent-exposed grid points and thus already accounts for buriedness. Consequently, shallow 
solvent exposed cavities have a lower active volume descriptor than buried enclosed closed cavities. 
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The results depicted in Figure 2 demonstrate that higher JEDIscore values do correlate with a larger 
binding site active volume V and a larger hydrophobicity descriptor Ha. 
Since the publication of the first large scale classification of protein binding sites by An et al,
41
 
numerous studies have been conducted in the field of pocket detection and analysis to improve 
understanding of the physicochemical properties that underlie protein-ligand interactions.
6,16,17,39
 The 
average volume of a druggable binding site was evaluated around 600 Å
3
,
41
 with maximum values 
around 900-1200 Å
3
.
39,40
 These estimates are in line with those computed with JEDI; the average 
volume of a binding site represented by the total number of active and partially active (ai >0) grid points 
was found to be 496  202 Å3 , with a maximum value of 1019 Å3. The results shown in Figure 2A 
depict the distribution of active volume (V) values for different categories of protein binding sites. As 
the active volume is the sum of the grid point volumes weighted by their activity, it is in general much 
smaller than the volume of the binding site. An average value for the whole dataset is V = 125  60 Å 3.  
The JEDI hydrophobicity descriptor shares similarities with the descriptor used by by Eyrisch et 
al. 
42,43
 In accordance with previous literature studies, druggable binding sites tend to have higher 
average hydrophobicity values (Ha = 0.72 ± 0.03) than non-druggable binding sites (Ha = 0.60 ± 0.04). 
This descriptor was found to be the most significant contribution to the JEDIscore values with a weight β 
almost five times larger than the α volume coefficient (Table 1). This observation is in a good 
agreement with the literature, where the apolar character of a cavity is usually the most important 
structural descriptor for druggability assessment.
13,39
 Indeed, a single hydrophobicity descriptor has 
been shown in some instances to be sufficient to distinguish druggable proteins from nondruggable 
proteins. 
16,24
 
 
Druggability scoring of diverse protein structures.  
The JEDI parameters were first optimized using multiple linear regressions and the elitist 
selection variant of the genetic algorithm methodology implemented in the python module PyEvolve.
26
 
JEDI druggability scores obtained at the end of the process are shown in Figure 3A. For comparison, 
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fpocket was used to calculate the druggability score of each protein in the training dataset (Figure 3B). 
The results suggest that JEDI predictions are slightly more accurate than those obtained using fpocket 
with a r
2
 of 0.63 ± 0.11 and 0.52 ± 0.13 respectively. Closer inspection of Figure 3A shows that JEDI 
discriminates fairly well sites categorized as ‘’undruggable’’ from those classified as ‘’druggable’’, but 
proteins in the ‘’difficult’’ category show a large scatter in JEDIscore values. Clearly, the exact 
‘’experimental’’ DCD druggability score assigned to a given protein can be debated, and this must be 
kept in mind when calibrating computational methods against this dataset. Additional tests were 
conducted by positioning the grid on buried or solvent exposed regions of the protein Malate 
Dehydrogenase (PDB 1BMD), where no apparent pockets were observed. The resulting JEDIscore values 
where invariably lower than 1.5.  
Detailed structural analyses of accurate and inaccurate druggability predictions for 
representatives druggable and non-druggable protein binding sites is useful to characterize the strengths 
and weaknesses of the present approach. Four representative structures were chosen for this purpose 
(Figure 4), and JEDI descriptor values for these structures are shown in table 4. Figure 4A represents the 
binding site of a malate dehydrogenase in complex with the coenzyme NAD (PDB 1BMD). This 
enzyme has been classified as nondruggable due to the difficulty of finding a drug-like compound able 
to compete with NAD for access to the binding site. The binding affinity of several known nucleotide 
inhibitors have been previously determined by enzymatic assays.
44
 The best competitive inhibitor is the 
cyclic nucleotide cAMP, presenting a Ki value 560 nM. If this protein is clearly evaluated as 
nondruggable by fpocket (score = 0.11), it remains challenging for other methodologies such as the 
NMR-based approach developed by Hadjuk and coworkers, which predicts the cavity as having an 
intermediate druggability.
12
  This is in line with the observed JEDIscore value for this system (5.1). The 
relatively high JEDIscore is largely due to the relative large active volume V of the binding site (157 Å
 3
), 
which is in the range of V values typical for druggable sites (Table 3, first row). Thus, that malate 
dehydrogenase is not considered druggable in practice may be more a reflection of the difficulty for a 
drug-like molecule to compete with NAD at a ca. 300 M expected intracellular concentration in 
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mammalian cells,
45
 rather than the occurrence of an unusually polar or shallow binding site.  An 
example of a correct nondruggable prediction is depicted in figure 4B for the binding site of Inositol 
Polyphosphate (IP) phosphatase.
46
 In addition to a small active volume due to a poor degree of 
enclosure, this small pocket presents a very low hydrophobicity score (Table 3, second row). This is 
mainly because of a Calcium ion in the binding site. A correctly predicted druggable cavity is shown in 
figure 4C. This mostly apolar well-enclosed pocket corresponds to the binding site of the S810L mutant 
mineralocorticoid receptor interacting with spironolactone (Table 3, third row).
47
 This inhibitor has 
shown  IC50 values in the range of 1.6 - 60 nM in a cell-based luciferase reporter assay.
48
 Lastly, figure 
4D depicts a druggable binding site that is incorrectly predicted to be ‘difficult’ to target. In addition to 
a high polarity caused by the presence of a zinc ion buried in the pocket, the binding site of carbonic 
anhydrase II is particularly small.
49
 Most successful carbonic anhydrase inhibitors exploit direct 
interactions with the buried zinc ion. The present version of JEDI does not account for potentially 
favorable metal-ligand interactions and this explains the discrepancy between the JEDIscore and DCDscore 
values (Table 3, fourth row). 
 
Sensitivity to minor structural variations, and computational cost.  
A potential concern at the outset of the project was that JEDIscore values would be unduly 
sensitive to minor structural variations that are typically observed when crystal structures of the same 
protein are solved and refined independently. A major motivation for the development of JEDI was to 
observe variability in JEDIscore between different structures of the same protein, only when 
conformational changes relevant for drug design are observed (e.g. a side-chain flip). This feature 
requires a subtle balance, on the one hand the methodology should not be too sensitive to very minor 
structural changes, but on the other hand it should be sufficiently sensitive to capture a fluctuation in 
druggability if the rearrangement is significant. The strategy here adopted was to evaluate the sensitivity 
of the JEDIscore values for comparable conformations of the same protein interacting with different 
ligands. The structural similarity was quantified by means of RMSD calculations on the backbone and 
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Cβ atoms of the binding site atoms of each protein. Selected proteins for which RMSD values of the 
different structures were less than 0.5 Å were retained for further analysis. Additionally, visualization of 
the binding sites confirmed that there was no noticeable difference in binding site conformation between 
the different selected structures. Figure 5A shows the distribution of JEDIscore values obtained by this 
analysis for a representative protein taken from the ‘nondruggable’, ‘difficult’ and ‘druggable’ 
categories of the DCD dataset. Although small fluctuations in JEDIscore are observed in the case of the 
difficult and the druggable binding site, the results suggest nevertheless a good reproducibility and 
robustness to insignificant structural changes. By contrast the fpocket methodology sometimes exhibits 
substantial variations in druggability that complicates interpretation of the scores (Figure 5B). As an 
additional test of sensitivity, the dependence of the JEDIscore values on the initial placement of the grid 
was assessed by evaluating the druggability of the same protein after translations of grid point 
coordinates by up to ±0.5 Å in the x, y, and z directions in Cartesian space. The druggability predictions 
were found to be quite insensitive to such translations, with fluctuations in the JEDIscore values in the 
range of 0.1. 
Next the computational cost of the JEDI calculations was assessed. An important consideration 
is that the calculations should not slow down too much molecular dynamics simulations. Benchmarks 
are shown in Table 4. If JEDI is used to monitor druggability values on the fly during an MD 
simulation, then it isn’t necessary to evaluate druggability at every time-step, as snapshots between 
successive times-steps are highly correlated. With druggability evaluation every 1 ps the time incurred 
is negligible, unless the MD simulation is parallelized across multiple processors. Likewise, single-point 
druggability estimates of a protein structure are far faster than alternative methodologies that take 
seconds to minutes.
14,16,50
 The implementation of MD simulation protocols biased with JEDI requires a 
druggability calculation at each time-step. In this case the performance loss is approximately a factor of 
1.4 to 2.7, depending on the number of processors used to speed-up the evaluation of the non-bonded 
energies. Evidently, further gains in efficiency could be achieved by parallelizing key subroutines in the 
JEDI code. Alternatively, multiple time-step algorithms schemes for collective variables as proposed 
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recently by Ferrarotti et al. could be used to decrease the computational cost further.
51
 The relative 
efficiency is also influenced by the choice of an implicit solvent model for this study, which 
dramatically speeds up the evaluation of non-bonded energies. Overall, the performance was deemed 
acceptable, given scope for future improvements.  
 
Application to a hidden pockets dataset.  
Validation of the methodology was pursued by analysis of a set of six proteins known to adopt 
distinct binding site conformations in the presence of different ligands (Figure 6). In each instance, two 
conformations for each protein were selected for druggability assessments. Protein structures were 
aligned and a grid defined from the largest ligand was used to compute a JEDIscore value for both 
conformations. In all instances the ligand atoms were ignored for druggability calculations. The results 
of this analysis are shown in Table 5. Human phenylethanolamine N-methyltransferase (hPNMT) is an 
enzyme involved in the synthesis of epinephrine from norepinephrine using the cofactor S-adenosyl- L-
methionine (SAM) to methylate the primary amine of noradrenaline. Two different hPNMT inhibitors, 1 
and 2, have been reported to inhibit the enzyme with  Ki values of 0.28 μM and 0.063 μM respectively 
(radiochemical assay).
52
 It has been shown that these two ligands bind to different conformations of the 
hPNMT binding site (Figure 6A). Both compounds engage in significant hydrophobic interactions, but 
the larger ligand (2) positions a p-chlorophenyl group in a cavity that is hidden in the hPNMT/1 
complex. Formation of the enlarged cavity in hPNMT/2 necessitates the rearrangement of the side-chain 
Lys57, as well as a small displacement of helix 3. The JEDI calculations were able to capture a 
favorable increase in druggability of ca. 0.8 units for the protein binding site conformation seen in 
hPNMT/2 in comparison with hPNMT/1. The change in druggability is due to a favorable increase in 
both V and Ha (Table 5, first row).  
The von Hippel-Lindau protein (pVHL) forms a complex with the proteins CUL2, Elongin B 
and C, and Rbx1. This complex is involved in the ubiquitination of the transcription factor hypoxia-
inducible factor (HIF-1), leading to proteasome-mediated degradation of HIF-1.53 Small molecules 3 
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and 4 have been reported to inhibit interactions between pVHL and HIF-1 with Kd values of 86.1 μM 
and 27.7 μM respectively (fluorescence polarization assay).19 The ligands occupy the same binding site, 
but a different orientation of Arg107 is observed, giving rise to a slightly more enlarged cavity in 
VHL/4 (Figure 6B). This translates into a slightly higher JEDIscore value for VHL/4 over VHL/3. This is 
because repositioning of Arg107 increased the value of H in VHL/4. However this is partially offset by 
a decrease in Va.  This is because the displacement of Arg107 exposes more grid points to the solvent, 
and as a consequence, grid points previously fully active become partially active (Table 5, second row).  
Serine/threonine-protein kinase or polo-like kinase 1 (PLK-1) is an enzyme involved in the 
regulation of cell division., The PLK-1 inhibitor 5 binds with an IC50 = 730 nM (fluorescence 
polarization assay) to the ATP binding site, and also to a subpocket that has been called the adaptive 
pocket, whereas the inhibitor 6 shows an IC50 of 530 nM (kinase enzymatic assay) and binds to the 
native purine-pocket of the active site (Figure 6C).
54,55
 However the larger active volume observed in 
the PLK-1/5 bound conformation is mainly due to active grid points around the methylpiperazine 
moiety of 5. These grid points are inactive in the PLK-1/6 complex because they are too solvent 
exposed. The adaptive pocket seen in PLK-1/6 is predicted to be less druggable than the native pocket 
seen in PLK-1/5 by ca. 0.8 units (Table 5, third row). 
Prostate specific membrane antigen (PSMA) is a glycoprotein overexpressed as a homodimer in 
many forms of prostate cancer. Compound 7 is an example of a first generation of PSMA inhibitors that 
binds the very polar binding site of PSMA with a Ki of 11 nM (fluorescence-based NAALADase 
assay).
56
 More recently, compounds belonging to the class of antibody recruiting small molecules 
targeting prostate cancer (ARM-P) have been reported, and compound 8 binds PSMA with a Ki of 0.02 
nM (enzymatic assay).
57,58
 A crystallographic structure of the PSMA/8 complex revealed that 8 binds to 
an open PSMA conformation that was not observed in the PSMA/7 complex. The large difference in 
binding affinities between 7 and 8 appears to be well reproduced by a large difference in JEDIscore 
values (Table 5, fourth row). However in this instance the active volume V is much larger than for a 
typical small molecule binding site and as a consequence the druggability score is strongly penalized by 
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Vdruglike. This indicates that the predictions for PSMA should be treated with care as the binding site 
differs substantially from those present in the training set. Compound 8 is unusual because it is made of 
a long flexible linker connecting a moiety positioned in the buried PSMA active site (Figure 6D blue 
square), and another moiety positioned in the arene binding site at the protein surface (Figure 6D black 
square). The JEDI analysis was therefore repeated by splitting the initial grid in two regions to predict 
the druggability of each pocket independently. A first grid was placed around the active site, and a 
second was located around the DNP pocket. A low score was observed for the active site in both 
instances (JEDIscore = 2.3 and 2.6 respectively), because of a very high polarity due to the presence of by 
several ions and polar and charged amino acids in the active site. The DNP pocket in PSMA/8 does 
score slightly higher (JEDIscore = 3.1) than the same region in the PSMA/7 complex (JEDIscore = 2.3) but 
the score remains small because the DNP pocket is relatively small. Thus the PSMA binding site is a 
good illustration of challenging conditions encountered when performing JEDI analysis of binding sites 
for ligand that depart from typical rule-of-five compliant small molecules. 
HIV-RT is an enzyme playing a crucial role in the replication of the HIV virus. Several non-
nucleoside RT inhibitors (NNRTIs) are available in the clinic for HIV treatments.
59-63
 Druggability 
predictions were compared for the NNRTI-binding pocket of the apo structure of HIV-1 RT and in 
complex with 9 (Figure 6E). This compound belongs to the second generation of NNRTIs and inhibits 
wild type HIV-RT with an IC50 of 2.1 nM (antiviral assay).
64,65
 The binding site of the HIV-RT/9 
complex was found to be one of the most druggable pocket analysed in this work. It is noteworthy that 
the NNRTI cavity is actually partially formed in the apo protein, and has an active volume of V = 192 
A
3 
The holo structure features an enlarged binding site and side chains rearrangements that increase the 
hydrophobicity Ha (Table 5, fifth row). 
Interleukin-2 (IL-2) is a cytokine playing a crucial role in the regulation of white blood cells of 
the immune system. The small molecule 10 binds to a pocket only partially present in the apo structure. 
An additional cavity is present in the holo complex and it forms by displacement of two residues, Phe42 
and Glu62 (Figure 6F).
66
 A similar pocket volume descriptor is observed for both apo and holo forms of 
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IL-2. However this time, a higher druggability score was predicted in absence of ligand, because the 
hydrophobicity Ha is lower in the IL-2/10 complex (Table 5, sixth row). This occurred because the 
motion of Phe42 and Glu62 promotes hydrogen bonding with Glu62 and Lys43, activating grid points 
close to polar atoms, thus decreasing hydrophobicity. 
Overall, the methodology is clearly able to correlate fluctuations in druggability score with 
noteworthy binding site conformational changes that have the potential to impact structure-based ligand 
design activities.  In five cases out of six, the conformation with the highest JEDIscore corresponds to the 
conformation that binds the most tightly bound ligand. Careful interpretation of the results is needed 
when considering unusual protein-ligand complexes, such as PSMA/8. Quantitative correlation with 
binding affinities is not expected since the ligands differ. Further, druggability is not exclusively linked 
to binding affinity. PSMA is an example of a binding site for which ligands with very low Ki values are 
known (7 and 8), but the low predicted druggability score is adequate since most of the binding affinity 
is achieved by means of strongly polar ligand moieties positioned in the active site. These in turn 
translate into inauspicious drug-like properties, such as low cell permeability. 
56,58
 
 
On the fly evaluation of druggability during MD simulations. 
Further tests were conducted with MD simulations of VHL. Druggability values were collected 
every ps over the course of a 50 ns simulation of apo VHL or VHL/3. The results are shown in Figure 7. 
The binding site druggability remained stable throughout the VHL/3 simulation, with an average 
JEDIscore of 7.80.6 which is consistent with the expected value from previous analyses (Table 5, row 
2). Clustering analysis reveals only one major binding site conformation (76% of the trafectory), that is 
depicted in Figure 7C (right panel). By contrast, the apo simulation shows an average druggability score 
of 5.70.8. Numerous structurally different binding site conformations are sampled. In the present MD 
simulations, the apo binding pocket is quickly obstructed by the rearrangement of Tyr98 and His110, 
inducing a drop of druggability. This could reflect inaccuracies in the protein force field used for the 
present study.  Dozens of clusters were identified and the most populated (JEDIscore ca. 6.3) is present in 
 20 
67% of the simulation (Figure 7C, left panel). This partially closed conformation is mainly stabilized by 
hydrogen bonds between the phenolic OH group of Tyr98 and the protein backbone. His110 is very 
flexible throughout the simulation. Surprisingly, significant side-chain rearrangements that partially 
block the binding site do not affect dramatically the JEDIscore values. This occurs here because the shift 
in position for Tyr98 has created a new hydrophobic sub-pocket that contributes favorably to the 
JEDIscore. However this sub-pocket is now occluded by Tyr98 and disconnected from the rest of the 
binding site. Further, the rest of the VHL binding site is still partially present, including the central 
pyrrolidine binding pocket. Binding site conformations that correspond to extreme druggability 
fluctuations seen in the apo simulation are depicted in figure 7D. In general, the apo conformations that 
present high JEDIscore values were found to be structurally similar to the VHL/3 conformation seen in 
the crystal structure. 
 
Biasing MD simulations with the JEDI potential. 
Umbrella sampling simulations were performed for apo VHL and VHL/3 using equation 15 and 
by varying force constant values for  and target JEDIscore values s0. No reweighting of the biased 
simulations was performed, thus all results presented below correspond to equilibrium properties of the 
biased Hamiltonians. The results are depicted in Figure 8. Apo simulations were biased to achieve a 
JEDIscore of 8, in expectation with the values previously observed for ligand bound complexes (Table 5, 
second row). Figure 8A (upper panel) indicates that the target druggability value is rapidly achieved in 
all instances. As expected fluctuations from the target value decrease with increased  values. The 
trajectory obtained using  = 2 000 kJ.mol-1.nm-2 was subjected to further clustering. The most 
populated clusters (51% of the overall trajectory) are very similar to the VHL/3 structure, with RMSD 
values always inferior to 2.0 Å. In the unbiased MD simulation of apo VHL, only 14% of the computed 
conformation exhibited an RMSD to the VHL/3 conformation that was smaller than 2.0 Å. Some 
clusters still contain conformations with Tyr98 pointing inside the binding site, but the occurrence is 
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greatly decreased. His110 was also found to be much less flexible.  It is apparent that the ligand binding 
site is almost fully formed in the most populated cluster of the biased apo VHL simulation (Figure 8A, 
bottom part).  
The umbrella sampling simulations of VHL/3 were performed to encourage the binding site to 
adopt more druggable conformations. A reference value s0 = 9 was selected based on the JEDIscore of 
VHL/4. Figure 8B upper part shows that higher  values are needed to achieve the desired s0 value. This 
indicates that the conformations with high JEDIscore values do not form spontaneously. The increase in 
JEDIscore values that is achieved correlates largely with the position of Arg107. This amino acid initially 
closes the binding site, but with the present bias, it shifts rapidly to a solvent exposed position, thus 
causing an enlargement of the binding site. This motion was rarely observed in unbiased MD 
simulations. 
Next, more significant structural rearrangements were sought by performing umbrella sampling 
simulations of apo VHL with s0 = 3.0. Results obtained with  = 2000 kJ.mol
-1
.nm
-2
 are shown in Figure 
9. Requesting such a low target druggability value forces VHL to largely collapse the binding site. Here 
the collapse is even more pronounced than observed in the unbiased apo VHL simulations, with the 
binding pockets of the isoxazole and pyrrolidine moieties completely masked.  Consequently, the pocket 
volume descriptor Va decreases, and the active volume V becomes sufficiently low such that the Vdruglike 
term penalizes the JEDIscore values. The hydrophobicity descriptor H is stable during the biased 
simulation, with an average value slightly lower than observed in the unbiased apo VHL simulation. 
The closure of the binding site has totally or partially inactivated numerous grid points that were 
previously in a buried cavity, leaving only a few active grid points at the protein surface and near polar 
groups. An illustration of the most populated cluster (73% of the trajectory) is depicted in figure 9B. 
 Umbrella sampling simulations of apo VHL were also performed by setting s0 = 10 and  = 2000 
kJ.mol
-1
.nm
-2 
to encourage the exploration of conformations with high druggability. The results are 
presented in Figure 10A. As observed previously, the simulation is rapidly sampling conformations in 
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the requested range of JEDIscore. As expected, Va and Ha are almost always higher than in the previously 
described simulations. However, larger fluctuations are observed in both descriptors throughout the 
biased simulation. An increase in hydrophobicity Ha is always offset by a decrease of the active volume 
descriptor Va and vice versa. Clustering analysis of the trajectory here reveals at least two significant 
distinct clusters (populations 18% and 8% respectively). The second cluster (Figure 10C) corresponds to 
a low Va / high Ha binding site conformation that is significantly different from the VHL/3 structure. 
The pyrrolidine pocket has collapsed and side-chains rearranged to expose hydrophobic groups to the 
surface. The first cluster (Figure 10B) corresponds to a conformation comparable to the VHL/3 holo 
structure. Additionally, Arg107 has adopted a solvent exposed position that contributes favorably to the 
JEDIscore as demonstrated previously (Table 5, second row). A significant difference that was not 
observed in previous simulations is the rearrangement of Arg69 in the left-hand side part of the binding 
site. This conformational rearrangement leads to a more extended cavity with high druggability scores. 
The flexibility of the left hand side pocket, has been recently discussed in the literature in the context of 
crystallographic structure analyses of multiple VHL ligand complexes,
67
 and Galdeano et al. have 
suggested that additional interactions between ligands and this part of the binding site may facilitate the 
development of improved VHL ligands.  
 
Docking ligands into JEDI computed conformations.  
 Several docking calculations were carried out to evaluate the utility of the conformational 
ensembles computed from the umbrella sampling simulations. Figure 11A depicts results obtained using 
the computed apo VHL conformation closest to the average conformation of the most populated cluster 
taken from an umbrella sampling simulation with s0 = 10.0 and  = 2000 kJ.mol
-1
.nm
-2
 (Figure 10B, 
top). Ligand 3 was found to adopt a pose that bears a substantial similarity with the crystallographic 
position of the ligand (RMSD of 3.6 Å, VINA binding energy of -5.6 kcal.mol
-1
). This is however not 
the top-scored pose which had a VINA binding energy of -6.2 kcal.mol
-1
. Qualitatively the discrepancy 
with the crystallographic binding mode is mostly due to a shift of the isoxazole ring of 3 that is involved 
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instead in stacking interactions with Tyr112. Closer inspection of the computed complex indicates that 
this binding mode is preferred because the computed ‘’left-hand side’’ VHL pocket that would normally 
host the isoxazole ring is too shallow. However, small fluctuations in pocket depth are apparent in 
snapshots that are present in the same cluster, and it is possible to manually select a snapshot with a left-
hand-side pocket that more closely resembles the crystallographic structure (RMSD of the binding-site 
sidechains depicted in Figure 11A to the crystallographic conformation is 1.3 Å, see Figure S2 for 
details). Repeating docking calculations on this conformation (Figure 11B) yields indeed a well scored 
pose (VINA binding energy -6.4 kcal.mol
-1
) that reproduces fairly well the crystallographic position of 
the ligand (RMSD of 2.1 Å) though  this is again not the top-scoring pose which had a VINA binding 
energy of -7 kcal.mol
-1
. As a control, the same docking protocol was also applied to the computed apo 
VHL conformation closest to the average conformation of the most populated cluster from an unbiased 
classical MD simulation (Figure 11C). As expected, the lowest-RMSD pose was significantly different 
from the crystallographic binding mode of 3 (RMSD of 5.4 Å, VINA binding energy -6.1 kcal.mol
-1
). 
The docking calculations were repeated allowing side-chain flexibility of Tyr98, Ile109 but no 
improvements were observed. This is likely because significant conformational changes involving both 
side-chain and backbone atoms rearrangements are necessary to form the ligand binding site from the 
apo protein conformations sampled from the unbiased MD simulation. Conversely, little improvements 
was seen in the RMSD of the ligands docked into the JEDI computed conformations with the aid of a 
flexible side-chain docking protocol, presumably because the binding site is already largely formed.  
 
Conclusions 
 A novel approach to assess protein binding site druggability has been developed. The fast, 
continuous and differentiable JEDI druggability estimator has been implemented in PLUMED and has 
been used as a collective variable in order to compute protein druggability at every integration step of a 
MD simulation.
23
 While the use of MD to sample protein conformations limits throughput, it offers the 
advantage of sampling more accurate protein conformations than those that may be generated by 
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alternative molecular modelling approaches. As discussed elsewhere, high accuracy is crucial if 
computed protein conformations are to be subject to follow-up virtual screens.
68
 The methodology is 
able to distinguish nondruggable, difficult and druggable pockets (r
2
 = 0.6±0.1), and is relatively 
insensitive to insignificant structural rearrangements in a binding site.  
Some limits in the estimator were exposed, for instance neglect of potential metal-ligand interactions. 
This could be remedied with additional structural descriptors. In addition, the present scoring function is 
only calibrated for detecting cavities that bind drug-like small molecules. JEDI was tested additionally 
on a dataset of hidden pockets for structurally diverse protein targets. The results show a good ability for 
the approach to detect conformational changes that influence the druggability of a protein binding site. 
With the present version of the method, care must be taken when performing this analysis on binding 
sites for ligands that depart from typical rule-of-five compliant small molecules.  
The main novelty of the approach lies in its potential to bias MD simulations with a JEDI force 
that will encourage a protein region to adopt conformations that match desired druggability scores. The 
results obtained through several umbrella sampling simulations of VHL indicate that JEDI enables the 
rapid sampling of ‘holo-like’ protein binding site conformations that are rarely seen in unbiased apo MD 
simulations. For structure-based drug design purposes this would be useful to identify tractable 
conformations in drug targets that may be otherwise considered undruggable from crystallographic 
analysis. An advantage of the approach over induced-fit docking/MD refinement protocols is that 
druggable cavities can be identified for targets that lack known ligands.
69
 JEDI also enables biased 
simulations of protein-ligand complexes. For structure-based drug design purposes, this would be useful 
to identify enlarged cavities that could accommodate a larger analog of an existing ligand.  
Further work will focus on replacing the GBSA implicit solvent model with explicit solvent 
models, and this is expected to improve the accuracy of the computed conformations.
70
 Additional work 
is also desirable to identify the most efficient and accurate docking protocols to use in combination with 
JEDI computed conformations. Clustering of the biased simulations in VHL has identified in many 
instances several structurally distinct conformations that match a given target druggability value. That 
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druggability is a degenerate collective variable was expected, and an exciting direction for this work is 
to couple the JEDI calculations with other collective variables to resolve distinct conformational states. 
This will facilitate the evaluation of the free energy of these hidden conformational states with respect to 
the native state conformation. This parameter is likely to be important for practical applications. 
Presumably the feasibility of targeting productively with a ligand a putative cryptic binding site hinges 
on an acceptable stability relative to the native state.
68
 Several enhanced sampling methodologies could 
in principle be suitable to this end,
71
 and progress towards this objective will be reported in due course.  
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Figure 1. Overview of the JEDI protocol. A) The region of space for druggability assessment is 
determined and all atom models of the protein (and ligand if present) are prepared as for a conventional 
MD simulation (1). A grid with a 1.5 Å spacing is placed around the region of interest (2). A 
druggability assessment is performed either for the input structure only, or repeatedly over the course of 
an MD simulation (3). B) For every druggability evaluation, all grid points are assigned an initial 
activity according to their distance to the ligand in the input structure. Next, grid points overlapping 
with protein atoms in the binding site region are inactivated fully or partially. Finally, solvent exposed 
grid points are inactivated fully or partially. C) Graphical representation of the switching functions 𝑆𝑣
𝑜𝑛 
(blue) and 𝑆𝑣
𝑜𝑓𝑓
(red) for k=1.0 and Δ=1.0. 
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Table 1. List of variables used to compute JEDIscore. 
Symbol Definition Value 
Vdruglike drug-like volume descriptor [0.0,1.0] 
Va pocket volume descriptor [0.0,∞]  
Ha pocket hydrophobicity descriptor [0.0,1.0] 
V active volume [0.0,∞] Å3 
ai activity of the grid point i [0.0,1.0] 
Hi hydrophobicity of the grid point i [0.0,1.0] 
Mapolar 
number of C and S atoms in the binding 
site region 
[0,∞] 
apolari 
Contact number with C and S atoms 
surrounding the grid point i 
[0.0,∞] 
Mpolar 
number of O and N atoms in the binding 
site region 
[0,∞] 
polari 
Contact number with O and N atoms 
surrounding the grid point i 
[0.0,∞] 
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Table 2. List of constants used to compute JEDIscore. 
Symbol Definition Value 
α PLS derived volume coefficient 5.31 
β PLS derived hydrophobicity coefficient 24.29 
γ PLS derived constant according to α and β -13.39 
Vg grid resolution 1.5 Å
3
 
CCmind 
distance below which a grid point is fully in 
close contact with the protein 
2.0 Å 
ΔCC 
distance interval over which a grid point is 
in partial contact with the protein 
0.5 Å 
Emin 
minimum number of grid points between a 
distance of 2.5 Å  and 3.5 Å from a grid 
point i interacting with the protein  
10 
ΔE 
interval over which a grid point is 
considered as buried in the cavity 
3 
BSmin 
minimum distance between a grid point and 
binding site atoms below which the maximal 
activity is fixed to 1 
2.0 Å 
ΔBS 
distance interval over which the maximal 
activity is fixed to 0 
6.0 Å 
 
constant used for minimum distance 
calculation 
50.0 Å 
CC2min 
minimum distance below which a grid point 
is overlapping the protein (for enclosure 
calculation) 
0.15 Å 
ΔCC2 
distance interval over which a grid point is 
in partial contact with the protein (for 
enclosure calculation) 
0.14 Å 
GP1min 
distance above which a grid point is 
considered for enclosure calculation 
2.5 Å 
ΔGP1 
distance interval over which a grid point is 
in partial contact with the protein 
0.5 Å 
GP2min 
distance below which a grid point is fully in 
close contact with the protein 
3.0 Å 
ΔGP2 
distance interval over which a grid point is 
in partial contact with the protein 
0.5 Å 
rhydro 
distance below which a grid point is fully in 
close contact with the protein (for 
hydrophobicity calculation) 
4.0 Å 
Δrhydro 
distance interval over which a grid point is 
in partial contact with the protein (for 
hydrophobicity calculation) 
0.5 Å 
Vmax volume below which Vdruglike is equal to 1 316 Å
3
 
ΔVmax 
volume interval over which Vdruglike goes 
from 1 to 0 
36 Å
3
 
Vmin volume below which Vdruglike is equal to 0 0.0 Å
3
 
ΔVmin 
volume interval over which Vdruglike goes 
from 0 to 1 
36 Å
3
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Figure 2. Boxplots of values of the (A) active volume V descriptor and (B) hydrophobicity descriptor 
Ha for the nondruggable, difficult and druggable systems of the training set. The box is defined using the 
first and the third quartile while the bar indicates the median. The edges of the boxplot represent the 
minimum and the maximum value observed for each category. 
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Figure 3. The correlation of computed druggability scores with DCD database druggability scores. A) 
Results for JEDI scores of the DCD training set. B) Results for fpocket scores of the DCD training set. 
Proteins discussed in the text, Figure 4 and Table 3 are represented with green crosses.  
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Figure 4. The relationship between JEDI druggability scores, binding site descriptors and ligand 
structures. A) Malate dehydrogenase is a nondruggable target predicted to have an intermediate 
druggability score.  It is in complex here with the coenzyme NAD (PDB 1BMD). B) IP phosphatase is a 
nondruggable binding site that is predicted to have a low druggability score. It is here in complex with 
inositol(1,4)-bisphosphate (PDB 1I9Z). C) Mineralocorticoid receptor is a druggable target that is 
predicted to have a high druggability score. It is here in complex with spironolactone (PDB 2OAX). D) 
Carbonic anhydrase II is a druggable target that is predicted to have a low druggability score. It is here 
in complex with ethoxzolamide (PDB 3CAJ). The protein surface has been colored according to polar 
(blue) and apolar (orange) atoms. The 3D ligand conformations are represented in red licorice. Green 
dots symbolize grid points, and grid points with activity values ai > 0 are depicted with small spheres. 
Calcium and zinc ions are respectively represented as grey and pink Van der Waals spheres. Pictures 
were prepared using the software VMD.
72
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Table 3. JEDI descriptor values for the structures depicted in Figure 5 
Protein V  / Å 3 Ha JEDIscore DCDscore 
Malate 
dehydrogenase 
157 0.64 5. 1 1 
IP phosphatase 34 0.57 0.7 1 
Mineralocorticoid 
receptor 
236 0.80 9.7 10 
Carbonic anhydrase 
II 
85 0.76 6.6 10 
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Figure 5. The sensitivity of druggability scores to small structural differences. The boxplots illustrate 
the fluctuations of the (A) JEDI and (B) fpocket druggability scores obtained from several highly 
similar conformations of a binding site for three different proteins. The DCD druggability score of each 
protein is given in parenthesis in the x-axis. The nondruggable, difficult and druggable systems selected 
for druggability assessment were respectively the dUTPase (PDB codes 1DUD, 1RN8, 1RNJ, 1SEH, 
1SYL, 2HR6, 2HRM), the Kringle 1 domain of human plasminogen (PDB codes 1CEA, 1CEB, 2PK4, 
1HPK) and the human sex hormone-binding globulin (PDB codes 1LHN, 1LHU, 1LHV, 1LHW). For 
the sake of consistency, only protein structures presenting a binding site identified by fpocket were 
selected. 
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Table 4. JEDI performance in ns/day for VHL (2278 atoms) and hPNMT (4057 atoms). The results 
were obtained using a cut-off of 20 Å for the neighbor list, and 100 ps simulations on an Intel Xeon E3-
1270 v3 (3.5GHz) processor. 
System 
Number 
of 
processors 
MD 
 
 
MD/JEDI 
monitor 
mode 
MD/JEDI 
bias 
 mode  
VHL 
1 1.3 1.3 0.9 
2 2.5 2.5 1.1 
4 3.1 3.0 1.1 
hPNMT 
1 0.5 0.5 0.4 
2 0.8 0.8 0.5 
4 1.6 1.3 0.6 
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Table 5. JEDI descriptor values for the hidden pocket dataset. 
Ligand Protein 
PDB 
code 
JEDI 
score 
V /A3 Ha Vdruglike 
1 hPNMT 1HNN 8.4 259 0.72 1.0 
2  2G8N 9.2 276 0.74 1.0 
3 VHL 3ZTD 8.2 118 0.80 1.0 
4  3ZTC 8.5 114 0.82 1.0 
5 PLK-1 2OWB 8.9 247 0.74 1.0 
6  3DB6 8.1 223 0.72 1.0 
7 PSMA 3IWW 0.0 493 0.54 0.0 
8  2XEG 4.7 341 0.55 0.8 
- HIV-RT 1DLO 8.5 192 0.76 1.0 
9  3M8P 9.6 213 0.78 1.0 
- IL-2 1M47 7.3 77 0.80 1.0 
10  1M48 6.2 78 0.75 1.0 
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Figure 6. Conformational variability in the hidden pocket dataset. (A) hPNMT in complex with 1 or 2, 
(B) VHL in complex with 3 or 4, (C) PLK-1 in complex with 5 or 6, (D) PSMA in complex with 7 or 8, 
(E) HIV-1 in complex with 9, (F) IL-2 in complex with 10. Protein regions that are similar in both 
conformations are represented in brown. 3D structures of the ligands are displayed in licorice. Pictures 
were prepared using the software VMD.
72
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Figure 7.  Druggability fluctuations during an MD simulations of apo VHL. Instantaneous values (thin 
lines) and 300 ps windowed averages (bold lines) of JEDIscore, Va and Ha during an MD simulation are 
represented in black, red and blue respectively for (A) apo VHL and (B) VHL/3. (C) The most 
representative conformation of apo VHL (left) and VHL/3 (right). (D) Representation of snapshots 
sampled at low (1) and high (2) druggability values in the apo VHL simulation (panel A). The protein 
surface was colored according to polar (blue) and apolar atoms (orange). Protein residues discussed in 
the text are highlighted in green sticks. The ligand is represented in red sticks. The crystallographic 
binding mode of the ligand is shown in transparent red. Pictures were prepared using the software 
VMD.
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Figure 8. Druggability fluctuations during umbrella sampling simulations of (A) apo VHL and (B) 
VHL/3. For clarity, only the running averages are shown for four different spring constants (red:  = 
500 kJ.mol
-1
.nm
-2
, blue:  = 1000 kJ.mol-1.nm-2, green:  = 2000 kJ.mol-1.nm-2, magenta:  = 5000 
kJ.mol
-1
.nm
-2
). An illustration of the most populated cluster from the simulation performed with  = 
2000 kJ.mol
-1
.nm
-2 
is depicted below each graph. All other symbols and representations are as in Figure 
7.  
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Figure 9.  Druggability fluctuations during a biased simulation of apo VHL with s0 = 3,  = 2000 
kJ.mol
-1
.nm
-2
. (A) Instantaneous values and running averages of JEDIscore, Va and Ha. (B) 
Representative conformation of the most populated cluster identified in the simulation. All other 
symbols and representations are as in Figure 7. 
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Figure 10. Druggability fluctuations in apo VHL umbrella sampling simulation with s0 = 10 and  = 
2000 kJ.mol
-1
.nm
-2
. (A) Running averages and instantaneous values of of JEDIscore, Va and Ha,  (B) The 
most representative conformation of the first (top) and second (bottom) most populated clusters 
observed during the simulation. All other symbols and representations are as in Figure 7. 
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Figure 11. Ligand docking in JEDI computed VHL conformations. (A) Pose of 3 (green sticks) 
presenting the lowest RMSD with the ligand in the crystallographic structure, docked in the computed 
apo VHL conformation closest to the average conformation of the most populated cluster from an 
umbrella sampling simulation with s0 = 10.0 and  = 2000 kJ.mol
-1
.nm
-2
. (B) Same as (A) but with a 
receptor conformation manually selected from the most populated cluster. (C) Same as (A) but docked 
in the computed apo VHL conformation closest to the average conformation of the most populated 
cluster from an unbiased MD simulation. Results obtained using Vina.
37
 The crystallographic pose is in 
red sticks.  All other symbols and representations are as in Figure 7.  
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